Zadnji put ažurirano :
19/11/2024
lijek protiv karcinoma   Irinotecan  
injekcija
Stabilizacija rješenja Stabilnost mješavine Stabilizacijski faktor Kompatibilnosti način davanja lijeka Bibliografija pdf
   Kemijska struktura  

Nekomercijalni   Nekomercijalni     

Zaštićeni nazivi su indikativni i sastav ekscipijensa može biti različit ovisno o državi i laboratorijima

Asinib Meksiko
Axinotecan Njemačka
Campto Indija, Austrija, Belgija, Danska, Finska, Francuska, Grčka, Hrvatska, Iran, Irska, Italija, Japan, Južna Afrika, Luksemburg, Madžarska, Malezija, Maroko, Nizozemska, Norveška, Poljska, Portugal, Španjolska, Švedska, Švicarska, Tajland, Tunis, Turska, Ujedinjeni Arapski Emirati, Velika Britanija
Camptosar Brazil, Kanada, S A D
Irinoliquid Austrija
Irnocam Brazil
Bibliografija   injekcija   Bibliografija : Irinotecan  
Vrsta Publikacija
1423 Časopis Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1617 Časopis Li WY, Koda RT.
Stability of irinotecan hydrochloride in aqueous solutions.
Am J Health-Syst Pharm 2002 ; 59: 539-544.
1662 Časopis Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1918 Časopis Dodds HM, Craik DJ, Rivory LP.
Photodegradation of irinotecan (CPT-11) in aqueous solutions : identification of fluorescent products and influence of solution composition.
J Pharm Sci 1997 ; 86, 12: 1410-1416.
1920 Časopis Akimoto K, Kaway A, Ohya K et al.
Photodegradation reactions of CPT-11, a derivative of campothecion, part i: chemical structure of main degradation products in aqueous solution.
Drug Stability 1996 ; 1: 118-122.
1921 Časopis Akimoto K, Kawai A, Ohya K.
Photodegradation reactions of CPT-11, a derivative of campothecion, part ii: photodegradation behaviour of CPT-11 in aqueous solution.
Drug Stability 1996 ; 1; 141-146.
1953 Časopis Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1976 Časopis Trissel LA, Xu QA.
Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration.
Int J Pharm Compound 2005 ; 9, 3: 238-241.
2027 Časopis Walker SE, Shirley L, Puodziunas A.
Simulation of Y-site compatibility of irinotecan and leucovorin at room temperature in 5% dextrose in water in 3 different containers.
Can J Hosp Pharm 2005 ; 58: 212-222.
2143 Časopis Dodds HM, Robert J, Rivory LP.
The detection of photodegradation products of irinotecan (CPT-11, Campto®, Camptosar®), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometry.
J Pharm Biomed Anal 1998 ; 17: 785-792.
2168 Časopis Ozdemir FA, Anilanmert B, Pekin M.
Spectrophotometric investigation of the chemical compatibility of the anticancer irinotecan-HCl and epirubicin-HCl in the same infusion solution.
Cancer Chemother Pharmacol 2005 ; 56, 5: 529-534.
2241 Časopis Thiesen J, Krämer I.
Physicochemical stability of irinotecan injection concentrate and diluted infusion solutions in PVC bags.
J Oncol Pharm Practice 2000 ; 6, 3: 115-121.
2340 Časopis Walker S.E, Law S, Puodziunas A.
Simulation of Y-Site Compatibility of Irinotecan and Leucovorin at Room Temperature in 5% Dextrose in Water in 3 Different Containers
Can J Hosp Pharm 2005 ; 58, 4: 212-222.
2671 Časopis Kaiser J, Thiesen J, Krämer I.
Stability of irinotecan-loaded eluting beads (DC Bead) used for transarterial chemoembolization.
J Oncol Pharm Practice 2010 ; 16: 53-61.
3129 Laboratorija Irinotécan (Campto®) – Résumé des caractéristiques du produits
Pfizer 2008
3369 Laboratorija Levofolinate de sodium Medac - Résumé des caractéristiques du produits
MEDAC France 2011
3670 Časopis Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30.
3873 Časopis Tan X, Hu J.
Incompatibility between irinotecan and fluorouracil injections
Am J Health-Syst Pharm 2016 ; 73:755.

  Mentions Légales